Correction: Hepatic origin of increased serum TFF3 in gastric cancer bearing subjects - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Elevated Serum TFF3 Levels in Gastric Cancer Patients Linked to Hepatic Source

  • By

  • Komei Kuge

  • Junko Mukohyama

  • Yoshimi Yasukawa

  • Yuko Ishibashi

  • Hiroki Masuda

  • Tomohiko Yasuda

  • Yasukazu Ohmoto

  • Hideyuki Takeshima

  • Akihisa Matsuda

  • Hiroshi Yoshida

  • Yasuyuki Seto

  • James R. Goldenring

  • Toshikazu Ushijima

  • Sachiyo Nomura

  • August 25, 2026

Share

Clinical Scorecard: Correction: Elevated Serum TFF3 Levels in Gastric Cancer Patients Linked to Hepatic Source

At a Glance

CategoryDetail
ConditionGastric Cancer
Key MechanismsElevated Serum TFF3 Levels
Target PopulationGastric cancer patients
Care SettingClinical oncology

Key Highlights

  • Correction of author's name from Junko Mukoyama to Junko Mukohyama
  • Focus on serum TFF3 levels in gastric cancer
  • Link to hepatic source of TFF3 levels

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Gastric cancer patients

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Hepatic origin of increased serum TFF3 in gastric cancer bearing subjects

            • by Komei Kuge, Junko Mukohyama, Yoshimi Yasukawa, Yuko Ishibashi, Hiroki Masuda, Tomohiko Yasuda, Yasukazu Ohmoto, Hideyuki Takeshima, Akihisa Matsuda, Hiroshi Yoshida, Yasuyuki Seto, James R. Goldenring, Toshikazu Ushijima, Sachiyo Nomura

            • August 25, 2026

            Related Content

            Implementation Strategies in Cascade Genetic Testing—The Devil Is in the Details

            Error in the Byline

            • August 27, 2026

            FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

            he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

            • by

            • August 26, 2026

            • 5 min